Alcon Inc. (NYSE:ALC) Faces Strategic Shift After STAAR Surgical Acquisition Falls Through

Core Insights - Alcon Inc. is a significant player in the ophthalmic industry, focusing on eye care products and surgical equipment, competing with major companies like Johnson & Johnson Vision and Bausch + Lomb [1] - Stifel Nicolaus has set a price target of $80 for Alcon, with the stock currently trading at $80.62, reflecting a slight decrease of approximately 0.77% from the target price [1][6] Company Developments - Alcon has terminated its agreement to acquire STAAR Surgical due to the failure to secure necessary stockholder votes, which may impact its market position and future growth strategies [2][6] - STAAR Surgical will continue as an independent publicly traded company, with a focus on profitable sales growth and enhancing distribution efficiencies, particularly expanding the use of its EVO ICL technology globally [3][6] Market Performance - Alcon's stock is currently priced at $80.62, showing a decrease of 0.49% or $0.40, with fluctuations between $79.68 and $81.11 today, and a 52-week high of $99.20 and a low of $71.55 [5] - Alcon's market capitalization is approximately $39.87 billion, with a trading volume of 1,128,034 shares [5]